NASDAQ · BIIB
Biogen Inc.
$249.65+$5.60 (+2.29%)
Biogen Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.53% below the high.
Loading market information…
NASDAQ · PRTA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Prothena Corporation plc’s quoted price sits in the lower half of its reported 52-week range, 24.75% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Prothena Corporation plc’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.23. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Prothena Corporation plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:42 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -$1.12-21.74% vs estimate | $2.83M-81.56% vs estimate |
|---|
| Q4 2024 | Feb 20, 2025 | -$1.08-5.88% vs estimate | $2.12M-71.82% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$1.10+6.78% vs estimate | $970.00K-21.14% vs estimate |
|---|
THE ANALYST VIEW
28 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $30.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$249.65+$5.60 (+2.29%)
Biogen Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.53% below the high.
$19.32+$0.03 (+0.16%)
Denali Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.23% below the high.
$4.01-$0.03 (-0.74%)
Annexon, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.15% below the high.
$2.37$0.00 (0.0%)
AC Immune S.A.’s quoted price sits in the lower half of its reported 52-week range, 39.23% below the high.
$2.29-$0.09 (-3.78%)
Acumen Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.39% below the high.
$1.30$0.00 (0.0%)
Anavex Life Sciences Corp.’s quoted price sits in the lower half of its reported 52-week range, 84.43% below the high.
$11.08+$0.01 (+0.09%)
ProMIS Neurosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.56% below the high.
$0.39-$0.00 (-1.22%)
Neumora Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 89.36% below the high.
